NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that Health
Canada has issued a Notice of Compliance for RYBREVANT in combination with
platinum-based chemotherapy for the first-line treatment of adult patients with
locally advanced or metastatic non-small cell lung cancer with activating
epidermal growth factor receptor Exon 20 insertion mutations. The Health Canada
NOC is based on results from the Phase 3, randomized, open-label, multicenter
PAPILLON study.

'The approval of RYBREVANT offers a promising and urgently needed new first-line
treatment option and represents significant advancement for those battling this
rare mutation,' said Nina Devito, Co-chair, Exon20 group-Canada.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX